Related content

Pharmacogenomic data submissions to the FDA: clinical case studies

By Trepicchio William L   Williams Grant A   Essayan David   Hall Sue T   Harty Lea C   Shaw Peter M   Spear Brian B   Wang Sue Jane   Watson Mark L  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 519-524

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data: FDA voluntary and required submission guidance

By Salerno Ronald A   Lesko Lawrence J  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 503-505

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: non-clinical case studies

By Leighton John K   DeGeorge Joseph   Jacobson-Kram David   MacGregor James   Mendrick Donna   Worobec Alexandra  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 507-511

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies

By Ruañño Gualberto   Collins Jerry M   Dorner Andrew J   Wang Sue-Jane   Guerciolini Roberto   Huang Shiew-Mei  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 513-517

Future Medicine

Access to resources Recommend Favorite

The European Commission, the EMEA and the US FDA have affirmed their commitment to regulatory cooperation

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 564, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite